Post-traumatic Stress DisorderMemocyclineNCT05902819
Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories
A study testing Imagery and Minocycline in people with Post-traumatic Stress Disorder and Cocaine Use Disorder, run by Psychiatric University Hospital, Zurich at 1 site in Switzerland.
Trial summary
An investigation of the effect of matrix-metalloproteinase-(MMP)-9 inhibition with minocycline on the reconsolidation of trauma- or cocaine-related memories Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Post-traumatic Stress Disorder, Cocaine Use Disorder
- What is being tested?
- Imagery and Minocycline
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 138 participants
- Where
- 1 siteSwitzerland
- Study dates
- 10 May 2023to 2 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD
- Current diagnosis of mild, moderate, or severe CUD according to DSM-5
- Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months
- Inclusion Criteria for the Clinical Controls (PTSD+CUD group):
- Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD
- Current diagnosis of mild, moderate, or severe CUD according to DSM-5
Show all 18Show fewer
- Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months
- Exclusion Criteria for the HC, PTSD, CUD, and PTSD+CUD groups:
- Women who are pregnant or breast feeding or intending to become pregnant during the course of the study or within 3 months after
- Other clinically significant concomitant disease states, e.g., renal failure (i.e., estimated glomerular filtration rate (eGFR; CKD-EPI) lower than 60 ml/min/1.73 m2), hepatic dysfunction (i.e., alanine transaminase (ALT) higher than 90 U/I for women or 110 U/I for men, aspartate aminotransferase (AST) higher than 74 U/I, and/or gamma-glutamyl transferase (γGT) higher than 70 U/I for women or 120 U/I for men), cardiovascular disease, etc.
- Presence or history of severe neurological disorders, head injuries or systemic/rheumatic disease
- Diagnosis of schizophrenia, bipolar disorder, or autism spectrum disorder according to DSM-5
- Pacemaker, neurostimulator or any other head or heart implants as well as MRI-incompatible metal parts or possibility of metal fragments in the body (MR safety)
- Claustrophobia (MR safety)
- Dependence on a hearing aid (MR safety)
- Inability to follow the procedures of the study, e.g., due to language problems
- Participation in another study with investigational drugs within the 30 days preceding and during the present study
- More than three suicide attempts in the past, a suicide attempt within the last 12 months and/or acute suicidality
Who cannot join
- Any current psychiatric diagnosis according to DSM-5 except for mild or moderate substance use disorder (SUD) for nicotine, and mild SUD for alcohol and cannabis
- Diagnosis of CUD according to DSM-5 (lifetime)
- Diagnosis of PTSD according to DSM-5 (lifetime)
- Allergy to minocycline or to any other ingredient in the named drug
- Current intake of the following medications interacting with minocycline: acitretin, acetylcystein, aluminiumhydroxid, amitryptiline, any antibiotics, antidiabetic drug such as sulfonylurea, atazanavir, atomoxetine, anticoagulant drugs from the coumarin type, barbiturates, bupropion, carbamazepine, ciclosporin A, isotretinoin, methotrexate, phenytoin, and theophylline
- Diagnosis of CUD according to DSM-5 (lifetime)
Show all 10Show fewer
- Current diagnosis of severe SUD for nicotine, moderate SUD for alcohol and cannabis, and mild SUD for all other substances according to DSM-5
- Diagnosis of PTSD according to DSM-5 (lifetime)
- Current diagnosis of severe SUD for alcohol or cannabis, and mild SUD for all other substances (except for nicotine) according to DSM-5
- Current diagnosis of severe SUD for alcohol or cannabis, and mild SUD for all other substances (except for nicotine) according to DSM-5
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital of Psychiatry Zurich, University of Zurich
Zurich, 8032
About this study
Official title: An Investigation of the Effect of MMP-9 Inhibition With Minocycline on the Reconsolidation of Intrusive Trauma- or Cocaine-related Memories
An investigation of the effect of matrix-metalloproteinase-(MMP)-9 inhibition with minocycline on the reconsolidation of trauma- or cocaine-related memories
Read the detailed description
Intrusive memories are involuntary recollections of past emotional events that can become pathological and persist over time, particularly in post-traumatic stress disorder (PTSD) and cocaine use disorders (CUD). Both PTSD and CUD are characterised by a hypersensitivity and -reactivity to cue-elicited memory reactivation and exhibit common neurological alterations, suggesting shared underlying mechanisms. As intrusive memories significantly contribute to maintaining the cycle of relapse in both disorders, it is important to find a way to attenuate them successfully. Research on memory reconsolidation has led to the development of different (pharmacological) approaches to disrupt the process, which have, however, yielded mixed and unspecific effects so far.
The present project aims to investigate the effect of MMP-9 inhibition with minocycline on the reconsolidation of intrusive memories in individuals with CUD or PTSD. Participants will be randomly assigned to a minocycline or placebo group. The study comprises a total of 5 visits during 3 weeks and one follow-up online survey (3 months after the intervention). Participants will receive the study medication before two imagery script-guided memory activation sessions. An ecological momentary assessment (EMA) approach will be employed to track intrusive memories, and glutamate concentration and neural activation will be measured with magnetic resonance spectroscopy (MRS) and functional magnetic resonance (fMRI), respectively, before and after the two imagery sessions.
- Being tested
- Imagery, Minocycline, Placebo
- Keywords
- memory reconsolidation blockade, minocycline, MMP-9 inhibition, PTSD, cocaine use disorder, placebo-controlled
- Medical subject headings
- Stress Disorders, Post-Traumatic, cyclopia sequence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ImageryBehavioural
Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
MinocyclineDrug
Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
PlaceboDrug
Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
| Study group | Role | What they receive |
|---|---|---|
| PTSD intervention group | Experimental | 30 individuals with PTSD will receive imagery with minocycline. Receives: Behavioral: Imagery; Drug: Minocycline |
| PTSD control group | Placebo comparator | 30 individuals with PTSD will receive imagery with placebo. Receives: Behavioral: Imagery; Drug: Placebo |
| CUD intervention group | Experimental | 30 individuals with CUD will receive imagery with minocycline. Receives: Behavioral: Imagery; Drug: Minocycline |
| CUD control group | Placebo comparator | 30 individuals with CUD will receive imagery with placebo. Receives: Behavioral: Imagery; Drug: Placebo |
| Healthy control group | No intervention | 30 healthy individuals who will not receive any intervention. |
| Clinical control group | No intervention | 30 individuals with both PTSD and CUD who will not receive any intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in intrusive memories frequency and features
Measured with the Intrusion Questionnaire, containing various items on intrusive memories frequency, arousal and distress as well as triggers, and responses.
Measured: Changes from baseline intrusive memories frequency and features after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2)
Change over time in self-reported intrusive memories frequency, arousal and distress
Captured with a short version of the Intrusion Questionnaire implemented as smartphone-based ecological momentary assessment (EMA), containing items on arousal and distress from self-reported intrusive memories.
Measured: EMA will be conducted for an average of 12 to 42 days (through study participation from baseline to 3 days after follow-up 1).
Secondary outcomes (21)
Changes in MRS signal parameters
Glutamate concentrations are measured using MRS in the amygdala in the PTSD group and in the nucleus accumbens in the CUD group.
Measured: Change from baseline MRS-measured glutamate concentrations after 9 to max. 39 days (follow-up 1).
Changes in fMRI Blood-Oxygenation-Level Dependent (BOLD) contrasts
fMRI BOLD contrasts between conditions (neutral/stress/trauma for the PTSD group; neutral/reward/drug for the CUD group) and between groups.
Measured: Changes from baseline fMRI BOLD contrasts after 9 to max. 39 days (follow-up 1).
Change in heart rate variability (HRV) during fMRI memory reactivation
HRV will be measured during the fMRI cue-reactivity paradigm (listening to trauma- or cocaine-related narratives compared to trauma- and cocaine-unrelated narratives).
Measured: Change from baseline HRV after 9 to max. 39 days (follow-up 1).
Change in respiratory rate during fMRI memory reactivation
Respiratory rate will be measured during the fMRI cue-reactivity paradigm (listening to trauma- or cocaine-related narratives compared to trauma- and cocaine-unrelated narratives).
Measured: Change from baseline respiratory rate after 9 to max. 39 days (follow-up 1).
Change in subjective rating of distress before and after memory reactivation
Current subjective distress will be measured with a visual analogue scale before and after listening to trauma- and cocaine-related narratives compared to trauma- and cocaine-unrelated narratives.
Measured: Change from baseline subjective distress after 9 to max. 39 days (follow-up 1).
Change in subjective rating of craving before and after memory reactivation
Current subjective craving will be measured with the Cocaine Craving Questionnaire (containing ten questions on current craving scaled from 0 to 10) before and after listening to cocaine-related narratives compared to cocaine-unrelated narratives.
Measured: Change from baseline craving after 9 to max. 39 days (follow-up 1).
Change in neurofilament light chain (NfL) levels
NfL levels will be measured in serum samples.
Measured: Change from baseline NfL levels after 9 to max. 39 days (follow-up 1).
Change in sphingolipid levels
Sphingolipid levels will be measured in plasma samples.
Measured: Change from baseline sphingolipid levels after 9 to max. 39 days (follow-up 1).
Change in inflammatory biomarker levels
Inflammatory biomarker levels will be measured in serum samples.
Measured: Change from baseline inflammatory levels after 9 to max. 39 days (follow-up 1).
Change in MMP-9 protein levels
MMP-9 protein levels will be measured in plasma samples.
Measured: Change from baseline MMP-9 protein levels after 9 to max. 39 days (follow-up 1).
Change in MMP-9 gene expression
MMP-9 gene expression will be measured in blood samples.
Measured: Change from baseline MMP-9 gene expression after 9 to max. 39 days (follow-up 1).
Heartrate variability
Heartrate variability (measured with a wearable (Fitbit)) predicted by the number and quality of intrusive memories experienced. Overall variability per person, in relation to overall health measured at Screening and Baseline as well as pre- and post-intervention variability will be assessed.
Measured: Will be measured during 9 to max. 39 days, from baseline until follow-up 1.
Sleep duration
Sleep duration (in minutes), trajectories over the course of the study periods, clusters of variations in duration and sleep quality (as averaged by the algorithm of Fitbit), according to medication/placebo, number of intrusions and overall health measured at Screening and Baseline.
Measured: Will be measured during 9 to max. 39 days, from baseline until follow-up 1.
Change in Obsessive Compulsive Cocaine Use Scale (OCCUS)
A 14-item self-report measure that assesses the current inability to control or resist cocaine-related thoughts and behaviors, frequency and impact of thoughts and impulses related to cocaine use, and the degree of interference caused by cocaine related thoughts and behaviors.
Measured: Change from baseline OCCUS score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
PTSD Checklist for DSM-5 (PCL-5)
A 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD in the last 2 weeks prior to the visit.
Measured: Change from baseline PCL-5 score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Beck Depression Inventory-II (BDI-II)
A 21-item self-report measure for assessing the severity of depression in the last 2 weeks prior to the visit.
Measured: Change from baseline BDI-II score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Pittsburgh Sleep Quality Index (PSQI)
A 19-item self-report measure which assesses sleep quality and disturbances in the last 2 weeks prior to the visit.
Measured: Change from baseline PSQI score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Global Assessment of Functioning (GAF)
A numeric scale used by the investigators to rate the current social, occupational, and psychological functioning of a participants. Scores range from 100 (extremely high functioning) to 1 (severely impaired).
Measured: Change from screening GAF score after both 10 to 50 days (follow-up 1) and approx. 4 months (follow-up 2).
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
A 30-item structured interview that is used to assess the 20 DSM-5 PTSD symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since the previous CAPS administration, and overall PTSD severity, and specifications for the dissociative subtype.
Measured: Change from screening CAPS-5 score after approx. 4 months (follow-up 2).
Changes in the Interview for Psychotropic Drug Consumption (IPDC)
A structured interview assessing self-reported patterns of use of common licit and illicit substances during the most representative month of the past year and, in the case of regular cocaine use, also specifically during the past month.
Measured: Change from screening IPDC after approx. 4 months (follow-up 2).
Voice-recorded language features of memories
Voice features and text-based features of reported autobiographical memories recorded during the screening to predict symptoms, with a primary focus on the prediction of intrusion-related features.
Measured: Assessed at screening
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2023
- Study start10 May 2023
- Primary completion2 Mar 2026
- Study completion2 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post-traumatic Stress DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, double-blind, placebo-controlled, parallel group, single center study
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 138 participants (actual)
Sponsor and investigators
- Lead sponsor
- Psychiatric University Hospital, Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich
- Responsible party
- Sponsor
- Investigators
- Boris B. Quednow, Prof. Dr., Principal investigator, Psychiatric University Hospital Zurich, University of ZurichBirgit Kleim, Prof. Dr., Principal investigator, University Hospital of Psychiatry Zurich, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05902819
- Sponsor's protocol ID
- 2022-01177
- Acronym
- Memocycline
- Status last verified
- Mar 2026
- First submitted
- 26 Apr 2023
- Last updated
- 6 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Investigation of the Effect of MMP-9 Inhibition With Minocycline on the Reconsolidation of Intrusive Trauma- or Cocaine-related Memories
- ClinicalTrials.gov ID
- NCT05902819
- Acronym / sponsor ID
- Memocycline / 2022-01177
- Keywords
- memory reconsolidation blockade, minocycline, MMP-9 inhibition, PTSD, cocaine use disorder, placebo-controlled
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 138 participants (actual)
- Lead sponsor
- Psychiatric University Hospital, ZurichUniversity, hospital or other
- Collaborators
- University of Zurich
- Study start
- 10 May 2023 (actual)
- Primary completion
- 2 Mar 2026 (actual)
- Study completion
- 2 Mar 2026 (actual)
- First posted
- 15 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An investigation of the effect of matrix-metalloproteinase-(MMP)-9 inhibition with minocycline on the reconsolidation of trauma- or cocaine-related memories
Detailed description
Intrusive memories are involuntary recollections of past emotional events that can become pathological and persist over time, particularly in post-traumatic stress disorder (PTSD) and cocaine use disorders (CUD). Both PTSD and CUD are characterised by a hypersensitivity and -reactivity to cue-elicited memory reactivation and exhibit common neurological alterations, suggesting shared underlying mechanisms. As intrusive memories significantly contribute to maintaining the cycle of relapse in both disorders, it is important to find a way to attenuate them successfully. Research on memory reconsolidation has led to the development of different (pharmacological) approaches to disrupt the process, which have, however, yielded mixed and unspecific effects so far.
The present project aims to investigate the effect of MMP-9 inhibition with minocycline on the reconsolidation of intrusive memories in individuals with CUD or PTSD. Participants will be randomly assigned to a minocycline or placebo group. The study comprises a total of 5 visits during 3 weeks and one follow-up online survey (3 months after the intervention). Participants will receive the study medication before two imagery script-guided memory activation sessions. An ecological momentary assessment (EMA) approach will be employed to track intrusive memories, and glutamate concentration and neural activation will be measured with magnetic resonance spectroscopy (MRS) and functional magnetic resonance (fMRI), respectively, before and after the two imagery sessions.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
- Model description
- Randomized, double-blind, placebo-controlled, parallel group, single center study
| Arm | Type | Receives |
|---|---|---|
| PTSD intervention group | Experimental | Behavioral: Imagery, Drug: Minocycline30 individuals with PTSD will receive imagery with minocycline. |
| PTSD control group | Placebo comparator | Behavioral: Imagery, Drug: Placebo30 individuals with PTSD will receive imagery with placebo. |
| CUD intervention group | Experimental | Behavioral: Imagery, Drug: Minocycline30 individuals with CUD will receive imagery with minocycline. |
| CUD control group | Placebo comparator | Behavioral: Imagery, Drug: Placebo30 individuals with CUD will receive imagery with placebo. |
| Healthy control group | No intervention | –30 healthy individuals who will not receive any intervention. |
| Clinical control group | No intervention | –30 individuals with both PTSD and CUD who will not receive any intervention |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (18 listed)
- Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD
- Current diagnosis of mild, moderate, or severe CUD according to DSM-5
- Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months
- Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD
- Current diagnosis of mild, moderate, or severe CUD according to DSM-5
Key exclusion criteria (10 listed)
- Any current psychiatric diagnosis according to DSM-5 except for mild or moderate substance use disorder (SUD) for nicotine, and mild SUD for alcohol and cannabis
- Diagnosis of CUD according to DSM-5 (lifetime)
- Diagnosis of PTSD according to DSM-5 (lifetime)
- Allergy to minocycline or to any other ingredient in the named drug
- Current intake of the following medications interacting with minocycline: acitretin, acetylcystein, aluminiumhydroxid, amitryptiline, any antibiotics, antidiabetic drug such as sulfonylurea, atazanavir, atomoxetine, anticoagulant drugs from the coumarin type, barbiturates, bupropion, carbamazepine, ciclosporin A, isotretinoin, methotrexate, phenytoin, and theophylline
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ImageryGuided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given. | Behavioural | CUD control group, CUD intervention group, PTSD control group, PTSD intervention group |
| MinocyclineSingle dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule. | Drug | CUD intervention group, PTSD intervention group |
| PlaceboSingle dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule. | Drug | CUD control group, PTSD control group |
Primary outcome
Changes in intrusive memories frequency and features
Time frame: Changes from baseline intrusive memories frequency and features after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2)
Measured with the Intrusion Questionnaire, containing various items on intrusive memories frequency, arousal and distress as well as triggers, and responses.
Change over time in self-reported intrusive memories frequency, arousal and distress
Time frame: EMA will be conducted for an average of 12 to 42 days (through study participation from baseline to 3 days after follow-up 1).
Captured with a short version of the Intrusion Questionnaire implemented as smartphone-based ecological momentary assessment (EMA), containing items on arousal and distress from self-reported intrusive memories.
21 secondary outcomes
Changes in MRS signal parameters
Time frame: Change from baseline MRS-measured glutamate concentrations after 9 to max. 39 days (follow-up 1).
Changes in fMRI Blood-Oxygenation-Level Dependent (BOLD) contrasts
Time frame: Changes from baseline fMRI BOLD contrasts after 9 to max. 39 days (follow-up 1).
Change in heart rate variability (HRV) during fMRI memory reactivation
Time frame: Change from baseline HRV after 9 to max. 39 days (follow-up 1).
Change in respiratory rate during fMRI memory reactivation
Time frame: Change from baseline respiratory rate after 9 to max. 39 days (follow-up 1).
Change in subjective rating of distress before and after memory reactivation
Time frame: Change from baseline subjective distress after 9 to max. 39 days (follow-up 1).
Change in subjective rating of craving before and after memory reactivation
Time frame: Change from baseline craving after 9 to max. 39 days (follow-up 1).
Change in neurofilament light chain (NfL) levels
Time frame: Change from baseline NfL levels after 9 to max. 39 days (follow-up 1).
Change in sphingolipid levels
Time frame: Change from baseline sphingolipid levels after 9 to max. 39 days (follow-up 1).
Change in inflammatory biomarker levels
Time frame: Change from baseline inflammatory levels after 9 to max. 39 days (follow-up 1).
Change in MMP-9 protein levels
Time frame: Change from baseline MMP-9 protein levels after 9 to max. 39 days (follow-up 1).
Change in MMP-9 gene expression
Time frame: Change from baseline MMP-9 gene expression after 9 to max. 39 days (follow-up 1).
Heartrate variability
Time frame: Will be measured during 9 to max. 39 days, from baseline until follow-up 1.
Sleep duration
Time frame: Will be measured during 9 to max. 39 days, from baseline until follow-up 1.
Change in Obsessive Compulsive Cocaine Use Scale (OCCUS)
Time frame: Change from baseline OCCUS score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
PTSD Checklist for DSM-5 (PCL-5)
Time frame: Change from baseline PCL-5 score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Beck Depression Inventory-II (BDI-II)
Time frame: Change from baseline BDI-II score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Change from baseline PSQI score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Global Assessment of Functioning (GAF)
Time frame: Change from screening GAF score after both 10 to 50 days (follow-up 1) and approx. 4 months (follow-up 2).
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Time frame: Change from screening CAPS-5 score after approx. 4 months (follow-up 2).
Changes in the Interview for Psychotropic Drug Consumption (IPDC)
Time frame: Change from screening IPDC after approx. 4 months (follow-up 2).
Voice-recorded language features of memories
Time frame: Assessed at screening
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Post-traumatic Stress Disorder
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Not yet recruitingPhase 3
Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Post-Traumatic Stress Disorder, PTSD
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Recruiting
Advancing Skills Through Consultation, Education, and Novel Technologies
PTSD - Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boris B. Quednow, Prof. Dr. principal investigator
Psychiatric University Hospital Zurich, University of Zurich
Birgit Kleim, Prof. Dr. principal investigator
University Hospital of Psychiatry Zurich, University of Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Imagery and Minocycline in people with Post-traumatic Stress Disorder and Cocaine Use Disorder, run by Psychiatric University Hospital, Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in intrusive memories frequency and features (time frame: Changes from baseline intrusive memories frequency and features after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2026.